Browse the evidence

Body weight decreased by 13.3% in patients treated with semaglutide compared to a marginal decrease of -2.6% in placebo-treated patients (P < .001).

Semaglutide can significantly aid in weight loss for obese patients with heart failure.

Long-acting GLP-1 agonists and incretin multi-agonists have demonstrated clinically significant efficacy in reducing body weight.

Practitioners may consider GLP-1 agonists and incretin multi-agonists as effective options for weight management in obese patients.

Automatic motivation and physical opportunities have direct effects on the duration of resistance training participation among GLP-1 medication users.

Interventions should enhance automatic motivation and ensure physical opportunities to increase resistance training duration.

AOM use prior to BMS is associated with significantly higher weight loss until the day of surgery (1.37 vs. 0.05; p = 0.04).

Practitioners may consider AOMs as a beneficial preoperative strategy for weight loss in bariatric surgery candidates.

GLP-1 based medications can achieve an average weight loss of 24%.

Practitioners can expect significant weight loss with GLP-1 medications.

GLP-1 agonists positively affect multiple obesity-related complications.

GLP-1 agonists can be used to manage various obesity-related health issues.

GLP-1-agonists significantly reduce the risk of cardiovascular endpoints in patients with overweight or obesity without diabetes, with a Number Needed to Treat (NNT) of 44.

GLP-1-agonists may be considered for reducing cardiovascular risk in non-diabetic patients with obesity.

Lifestyle therapies, including weight loss and diet, are effective for managing obesity-related hypertension.

Encouraging weight loss and dietary changes can be beneficial for patients with obesity-related hypertension.

Incretin drug therapy can produce significant weight loss in properly selected individuals.

Clinicians should consider incretin therapy for weight loss in appropriately selected patients.

New dietary interventions are poised to overtake traditional strategies as the ideal approach to achieving sustained weight loss for obesity-associated hypertension patients.

Practitioners should consider implementing new dietary interventions for better weight loss outcomes in patients.

Eine Gewichtsabnahme kann die urogynäkologischen Symptome verbessern, bei 5–10% Gewichtsreduktion wird ein Rückgang der Inkontinenzepisoden bis zu 60% beschrieben.

Gewichtsreduktion sollte als Therapieoption zur Verbesserung urogynäkologischer Symptome in Betracht gezogen werden.

Bariatric surgery is the most effective treatment for obesity, yielding sustainable weight loss of about 20-30%.

Bariatric surgery should be considered for patients with obesity seeking significant weight loss.

GLP-1 receptor agonist semaglutide 2.4 mg and dual GLP-1 and GIP agonist tirzepatide have raised the bar for weight loss efficacy in obesity pharmacotherapies.

Clinicians should consider GLP-1 and GIP agonists as effective options for obesity treatment.

Combinations of GLP-1 RA, GIP, and glucagon RA (retatrutide) have shown weight loss efficacy approaching that of bariatric surgery.

Combination therapies may offer significant weight loss benefits similar to surgical options.

Pharmacotherapy is highly effective in reducing body weight and improving metabolic parameters.

Pharmacotherapy should be considered as a key component in obesity treatment plans.

Psychological support, including cognitive-behavioral therapy, increases patient adherence and improves long-term outcomes.

Incorporating psychological support can enhance treatment adherence and effectiveness.

Second-generation drugs for obesity treatment can achieve weight loss of 15-25%, comparable to bariatric surgery.

Healthcare professionals can consider second-generation drugs as effective options for weight management in obese patients.

GLP-1 receptor agonists can achieve weight loss of 15-17% with a good safety profile.

GLP-1 receptor agonists are a viable treatment option for weight loss in obese patients.

Tirzepatide can achieve weight loss of up to 22.5% at the highest doses.

Tirzepatide represents a potent option for significant weight loss in obese patients.

Obesity has been associated with an increased risk of all-cause and cardiovascular mortality.

Awareness of the mortality risks associated with obesity is essential for patient management.

Once-weekly GLP-1RA therapy can produce substantial weight loss over prolonged treatment (up to 23% at 72 weeks), alongside improvements in metabolic outcomes and reduced cardiometabolic risk.

GLP-1RA therapies can be effective for significant weight loss and improving metabolic health in obese patients.

Inkretin-basierte Medikamente (GLP-1- und GIP/GLP-1-Rezeptoragonisten) und SGLT-2-Inhibitoren (SGLT2i) ermöglichen eine bislang nicht erreichte Gewichtsreduktion und reduzieren nachweislich kardiovaskuläre Ereignisse (MACE).

Practitioners should consider these medications as effective options for weight management and cardiovascular risk reduction.

Die Kombination von GLP-1-Rezeptoragonisten und SGLT2i zeigt additive Vorteile und wird leitliniengerecht bei Typ-2-Diabetes mit hohem Risiko empfohlen.

Healthcare providers should consider this combination therapy for high-risk type 2 diabetes patients.

Cognitive–behavioral methods focusing on emotional eating lead to greater improvements in emotional eating and related weight and waist circumference reductions compared to education-based approaches.

Practitioners should consider implementing cognitive-behavioral strategies that focus on emotional eating in obesity treatment programs.